ACIP's Vacancy Leaves Pharmacists Navigating COVID-19 Confusion

This episode, "ACIP's Vacancy Leaves Pharmacists Navigating COVID-19 Confusion," features the panel unpacking what ACIP's stalled quorum means for coverage, stocking, and patient guidance.

Dr. Jeff Goad turns the conversation to this season's vaccine landscape, noting that public attention toward COVID-19 has waned even as the virus persists. He explains that VRBPAC, the FDA's vaccine advisory subcommittee, settled on the XFG strain for the 2026-2027 formulation back in May. However, Goad notes, the CDC's Advisory Committee on Immunization Practices has lacked a functioning quorum to vote on who should receive the vaccine or how doses should be covered. He asks Curlin what that gap means for clinicians, pharmacists, and patients this fall.

Curlin describes the situation as an erosion of the country's vaccine advisory structure. Without ACIP guidance, he explains, a disconnect emerges between vaccine availability on pharmacy shelves and clear direction on how it should be used. Curlin outlines several downstream consequences. Insurance companies will no longer be required to cover the vaccine in full, he says, so coverage will instead follow standard drug formulary grids. That shift, Curlin warns, means patients may face unpredictable co-pays or out-of-pocket costs. He also points to a loss of unified guidance. Clinicians and patients now must consult a patchwork of sources rather than a single trusted authority, producing what Curlin calls a fragmentation of the public health message. Finally, he notes that uncertainty around guidance and expected uptake makes it harder for hospitals and pharmacies to stock vaccines appropriately, which could affect availability later in the season.

Goad agrees, adding that confusion is the enemy of vaccine uptake. The more clinicians clear up myths, he says, the more likely patients are to get vaccinated. Goad observes that with the CDC's traditional role diminished, groups like the American Academy of Family Physicians and regional clinical alliances have stepped in. Curlin agrees this leaves some resources available, but acknowledges it still adds to overall confusion.

Our next episode, "How mRNA and Protein-Based COVID-19 Vaccines Actually Work," breaks down the science distinguishing mRNA and protein-based platforms.